Oakland, Calif. - Social media influencers have been making bold claims that GLP-1 medications — the same drugs used for weight loss and diabetes — can also prevent Alzheimer's disease. But a leading neurologist says the science tells a more nuanced story.
Dr. Peter Ljubenkof, director of UCSF's Alzheimer's Infusion Core and associate professor of neurology, sat down to break down the findings from several recent clinical studies.
"We don't know if there's a specific connection between GLP-1 drugs and Alzheimer's per se," Ljubenkof said.
What researchers do know is that in large clinical trials involving patients with diabetes, GLP-1 drugs were effective at controlling blood sugar — and patients who achieved better blood sugar control also showed a cognitive benefit.
"It seemed to protect from memory loss," Ljubenkof said.
But he was quick to draw an important distinction. Alzheimer's is just one of many causes of memory loss and dementia, and the question of whether GLP-1 drugs have a specific impact on the biology of Alzheimer's — the plaques and tangles that form in the brain — remains unanswered.
Two new large-scale studies have now looked at that question directly, and the results were not what social media would suggest. In patients with early symptomatic Alzheimer's disease, semaglutide — one of the most widely used GLP-1 drugs — did not appear to reduce symptoms or slow cognitive decline.
"We don't think that there's a major impact on Alzheimer's biology specifically," Ljubenkof said, "but there may still be a brain protective effect in certain subsets of people, particularly people with diabetes."
As for why GLP-1 drugs appear to benefit the brain in diabetes patients, Ljubenkof said it likely comes down to a combination of factors. The drugs influence insulin release and help control blood sugar, which is known to benefit the brain. They also change eating behavior — reducing appetite and suppressing what he called "food noise," the persistent mental pull toward rewarding foods. Both effects can improve cardiovascular health, which in turn benefits the brain.
For people with a family history of Alzheimer's who are wondering whether they should take GLP-1 drugs as a preventive measure, Ljubenkof urges caution.
"We don't have data to support a specific use of GLP-1 drugs in preventing Alzheimer's disease or reducing symptoms of Alzheimer's disease," he said.
His bigger message: cardiovascular health matters. Controlling diabetes, blood pressure, and cholesterol are all meaningful steps toward protecting the brain. GLP-1 drugs may play a role in that — but as a tool for managing cardiovascular and metabolic conditions, not as a targeted Alzheimer's treatment.
The Source: Interview with Dr. Peter Ljubenkof, director of UCSF's Alzheimer's Infusion Core and associate professor of neurology; study results from NIH Evoke trials on GLP-1 and Alzheimer's.